White Paper

Gene To IND In 12 Months Without Increased Risk

By Abdelaziz Toumi, PhD, Head of Customer Solutions, Ibex® Design & Develop, and Atul Mohindra, PhD, Head of Bio-Manufacturing, Research & Development

Gene Laboratory

Small pharma companies are making major breakthroughs in patient treatment, yet they still face considerable challenges in developing their candidates from discovery to commercial phase. In a recent survey by Biopharma Dive, the three top concerns for small biotechs were moving quickly enough without adding risk to their programs, procuring the capital resources necessary to finance their product’s long-term success, and finding a partner with the resources and capacity to bring their idea from gene to IND.1 Unexpected delays or poor-quality development and manufacturing work could create issues that are too costly to overcome. Yet, there are a variety of gene to IND programs on the market to satisfy a small biotech’s need for speed, so you need to carefully assess which program matches your technical expectations as well as your risk adversity profile.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: